Bias toward European-centric samples and bottleneck in multi-ethnic refractive error prediction Refractive error is a major polygenic ocular disease that causes visual impairment worldwide. However, existing genome-wide association study (GWAS) guidelines have been heavily skewed toward samples of European ancestry, creating a serious blind spot that fails to quantify the unique genetic architecture and allele frequency variation of other populations such as Asian or African groups. The inability to computationally control inter‑ethnic genetic background noise has long been a technical bottleneck preventing the establishment of precise ophthalmic pipelines that accurately score myopia susceptibility for each population.

Deployment of a million‑person multi‑ethnic GWAS: identification of >400 novel genomic variants Our study, published in Nature Genetics on 1 June, assembled a multi‑ethnic cohort of over one million individuals from eight continents to neutralize this genetic bias. The team improved genotype imputation fidelity across groups and performed in‑silico mapping. As a result, more than 400 previously missing variants were pinpointed, and we demonstrated that they are causally and strongly linked to axial length and downstream molecular pathways governing refractive regulation.

Recalibration of polygenic risk scores (PRS) and achievement of ancestry‑agnostic clinical stratification Using the newly identified multi‑ethnic variant matrix as a backbone, the investigators refined a polygenic risk score model that back‑calculates the risk curve for refractive error. By computationally correcting intra‑ancestry rendering differences, they eliminated false‑positive prognostic noise when applying the model to other ancestries, dramatically improving predictive accuracy for myopia and hyperopia onset thresholds. Clinicians can now stratify high‑risk patients using only multidimensional genomic inputs within a precision‑ophthalmology screening framework.

Establishment of a programmable ocular health‑management standard and launch of next‑generation CDx platform The integrated ophthalmic genetics and population omics data repository redefines myopia‑prevention guidelines from a reactive vision‑correction approach to a programmable eye‑care infrastructure that filters individual genetic susceptibility to generate customized spectacle prescriptions and environmental‑control solutions. Multinational pharmaceutical and optical companies have incorporated computational correction coefficients to filter genetic false‑positive noise in clinical‑trial participants for next‑generation pediatric myopia‑inhibition therapeutics. The resulting variant‑sensitivity matrix will serve as a master reference to accelerate global regulatory approval timelines for future digital‑health and companion‑diagnostic (CDx) platforms.